# Galderma

Type: Company (GALD)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/galderma
Canonical HTML page: https://getbiobrief.com/entity/galderma

## Recent coverage (1 stories)

### Galderma's Alastin Brings Dual-Action Peptide Regeneration to 4 Asian Markets
2026-08-03 06:23:53 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Galderma introduces its premium Alastin skincare line, featuring proprietary TriHex peptide technology, across four key Asia Pacific markets. The dual-action mechanism—clearing damaged collagen while stimulating new synthesis—positions Alastin as a pioneer in regenerative aesthetic science, building on recent launches in China and Australia.
Full story: https://getbiobrief.com/story/galderma-alastin-trihex-peptide-skincare-asia-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.